Neuroderm Ltd Stock Price, News & Analysis (NASDAQ:NDRM)

$38.85 -0.05 (-0.13 %)
(As of 11/24/2017 04:30 AM ET)
Previous Close$38.90
Today's Range$38.85 - $38.95
52-Week Range$15.20 - $38.95
Volume200,900 shs
Average Volume418,712 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Neuroderm Ltd (NASDAQ:NDRM)

Neuroderm Ltd logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Receive NDRM News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NDRM
CUSIPN/A
Phone+972-8-9462729

Debt

Debt-to-Equity RatioN/A
Current Ratio17.69%
Quick Ratio17.69%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.12)
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.69%
Return on Assets-42.41%

Miscellaneous

Employees55
Outstanding Shares26,350,000

Frequently Asked Questions for Neuroderm Ltd (NASDAQ:NDRM)

What is Neuroderm Ltd's stock symbol?

Neuroderm Ltd trades on the NASDAQ under the ticker symbol "NDRM."

How were Neuroderm Ltd's earnings last quarter?

Neuroderm Ltd (NASDAQ:NDRM) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.13. View Neuroderm Ltd's Earnings History.

Where is Neuroderm Ltd's stock going? Where will Neuroderm Ltd's stock price be in 2017?

8 brokerages have issued 1 year price targets for Neuroderm Ltd's shares. Their forecasts range from $39.00 to $70.00. On average, they expect Neuroderm Ltd's share price to reach $45.86 in the next twelve months. View Analyst Ratings for Neuroderm Ltd.

What are Wall Street analysts saying about Neuroderm Ltd stock?

Here are some recent quotes from research analysts about Neuroderm Ltd stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (10/18/2017)
  • 2. Cowen Inc analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Who are some of Neuroderm Ltd's key competitors?

Who are Neuroderm Ltd's key executives?

Neuroderm Ltd's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • , Bio & Compensation - 
  • Tami Yardeni, Chief Operating Officer
  • , Bio & Compensation - 
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • , Bio & Compensation - 
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did Neuroderm Ltd IPO?

(NDRM) raised $45 million in an initial public offering on Friday, November 14th 2014. The company issued 4,500,000 shares at $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Who owns Neuroderm Ltd stock?

Neuroderm Ltd's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Omni Partners LLP (4.24%), JPMorgan Chase & Co. (2.81%), OxFORD Asset Management LLP (2.23%), Allianz Asset Management GmbH (2.06%), Vivaldi Asset Management LLC (1.60%) and GABELLI & Co INVESTMENT ADVISERS INC. (1.38%). View Institutional Ownership Trends for Neuroderm Ltd.

Who sold Neuroderm Ltd stock? Who is selling Neuroderm Ltd stock?

Neuroderm Ltd's stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc. View Insider Buying and Selling for Neuroderm Ltd.

Who bought Neuroderm Ltd stock? Who is buying Neuroderm Ltd stock?

Neuroderm Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Omni Partners LLP, JPMorgan Chase & Co., OxFORD Asset Management LLP, Allianz Asset Management GmbH, Vivaldi Asset Management LLC, GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC and Commonwealth of Pennsylvania Public School Empls Retrmt SYS. View Insider Buying and Selling for Neuroderm Ltd.

How do I buy Neuroderm Ltd stock?

Shares of Neuroderm Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuroderm Ltd's stock price today?

One share of Neuroderm Ltd stock can currently be purchased for approximately $38.85.

How big of a company is Neuroderm Ltd?

Neuroderm Ltd has a market capitalization of $1.02 billion. Neuroderm Ltd employs 55 workers across the globe.

How can I contact Neuroderm Ltd?

Neuroderm Ltd's mailing address is 3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance, REHOVOT, 7670212, Israel. The biotechnology company can be reached via phone at +972-8-9462729.


MarketBeat Community Rating for Neuroderm Ltd (NDRM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Neuroderm Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Neuroderm Ltd (NASDAQ:NDRM)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.86$45.86$45.86$43.75
Price Target Upside: 18.04% upside18.04% upside18.95% upside84.99% upside

Consensus Price Target History for Neuroderm Ltd (NASDAQ:NDRM)

Price Target History for Neuroderm Ltd (NASDAQ:NDRM)

Analysts' Ratings History for Neuroderm Ltd (NASDAQ:NDRM)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies Group LLCReiterated RatingBuy$42.00LowView Rating Details
8/2/2017Roth CapitalDowngradeBuy -> Neutral$33.00 -> $39.00LowView Rating Details
7/24/2017Raymond James Financial, Inc.DowngradeOutperform -> Market Perform$39.00HighView Rating Details
7/21/2017Deutsche Bank AGInitiated CoverageBuy -> Buy$47.00HighView Rating Details
6/14/2017CIBCUpgradeMarket Perform -> Outperform$42.00HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$42.00HighView Rating Details
3/7/2017Citigroup Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017Cowen IncBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Neuroderm Ltd (NASDAQ:NDRM)

Earnings by Quarter for Neuroderm Ltd (NASDAQ:NDRM)

Earnings History by Quarter for Neuroderm Ltd (NASDAQ NDRM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuroderm Ltd (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20172($0.51)($0.40)($0.46)
Q3 20172($0.58)($0.50)($0.54)
Q4 20172($0.62)($0.50)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Neuroderm Ltd (NASDAQ:NDRM)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neuroderm Ltd (NASDAQ NDRM)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Neuroderm Ltd (NASDAQ NDRM)

Source:
DateHeadline
Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)
www.americanbankingnews.com - November 22 at 5:26 AM
Neuroderm Ltd (NDRM) Given Average Rating of "Buy" by AnalystsNeuroderm Ltd (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 8:31 AM
NeuroDerm (NDRM) and The Competition Financial ContrastNeuroDerm (NDRM) and The Competition Financial Contrast
www.americanbankingnews.com - October 30 at 9:22 PM
NeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by BrokeragesNeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 11:01 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)
globenewswire.com - October 19 at 6:40 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDermMitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm
feeds.benzinga.com - October 18 at 4:46 AM
Zacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - October 15 at 12:08 AM
Zacks Investment Research Downgrades Neuroderm Ltd (NDRM) to SellZacks Investment Research Downgrades Neuroderm Ltd (NDRM) to Sell
www.americanbankingnews.com - October 8 at 11:50 PM
Critical Review: NeuroDerm (NDRM) versus Its CompetitorsCritical Review: NeuroDerm (NDRM) versus Its Competitors
www.americanbankingnews.com - October 2 at 2:22 AM
NeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 30 at 10:42 AM
NeuroDerm Ltd. (NDRM) Short Interest UpdateNeuroDerm Ltd. (NDRM) Short Interest Update
www.americanbankingnews.com - September 30 at 3:26 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)
globenewswire.com - September 14 at 8:11 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - September 13 at 7:01 AM
NeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 5 at 10:44 AM
NeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in AugustNeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in August
www.americanbankingnews.com - August 29 at 1:06 AM
Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)
www.prnewswire.com - August 23 at 9:05 AM
Equities Analysts Offer Predictions for NeuroDerm Ltd.s Q3 2017 Earnings (NDRM)Equities Analysts Offer Predictions for NeuroDerm Ltd.'s Q3 2017 Earnings (NDRM)
www.americanbankingnews.com - August 18 at 6:42 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLCNeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 14 at 6:06 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from BrokeragesNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
NeuroDerm Announces Second Quarter 2017 Financial ResultsNeuroDerm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:15 AM
Roth Capital Downgrades NeuroDerm Ltd. (NDRM) to NeutralRoth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral
www.americanbankingnews.com - August 2 at 8:44 AM
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - August 2 at 6:14 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - NasdaqNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - Nasdaq
www.nasdaq.com - July 27 at 4:43 AM
Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.
finance.yahoo.com - July 27 at 4:43 AM
NeuroDerm (NDRM) Agrees to be Acquired by Japans Mitsubishi Tanabe Pharma for $1.1BNeuroDerm (NDRM) Agrees to be Acquired by Japan's Mitsubishi Tanabe Pharma for $1.1B
www.streetinsider.com - July 26 at 4:02 AM
NeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe PharmaNeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe Pharma
www.rttnews.com - July 26 at 4:02 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in SessionNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session
finance.yahoo.com - July 26 at 4:01 AM
Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.comBiotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.com
www.thestreet.com - July 25 at 6:04 AM
NeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - NasdaqNeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - Nasdaq
www.nasdaq.com - July 25 at 6:04 AM
Japans Nikkei inches up, caught in tight range before Fed meetingJapan's Nikkei inches up, caught in tight range before Fed meeting
finance.yahoo.com - July 25 at 6:04 AM
Aussie stocks lead a rebound for Asian markets as dollar steadiesAussie stocks lead a rebound for Asian markets as dollar steadies
finance.yahoo.com - July 25 at 6:04 AM
Nikkei edges down before Fed; Topix ends below key technical levelNikkei edges down before Fed; Topix ends below key technical level
finance.yahoo.com - July 25 at 6:04 AM
Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"
www.americanbankingnews.com - July 24 at 2:52 PM
NeuroDerm To Be Bought By Japans Mitsubishi Tanabe Pharma For $1.1 Blm In CashNeuroDerm To Be Bought By Japan's Mitsubishi Tanabe Pharma For $1.1 Blm In Cash
www.rttnews.com - July 24 at 7:10 AM
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in CashNeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
finance.yahoo.com - July 24 at 7:10 AM
Mitsubishi Tanabe Pharma to buy Israels Neuroderm for $1.1 blnMitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln
finance.yahoo.com - July 24 at 7:10 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AGNeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AG
www.americanbankingnews.com - July 22 at 8:14 PM
Deutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.comDeutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.com
www.streetinsider.com - July 22 at 6:50 AM
Market Limps Into WeekendMarket Limps Into Weekend
finance.yahoo.com - July 22 at 6:50 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from AnalystsNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 17 at 11:59 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per ShareNeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - July 10 at 2:15 PM
Results of NeuroDerms ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of NeurologyResults of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
feeds.benzinga.com - June 27 at 7:55 AM
Firm Fighting Parkinsons Hails Reviews, UpgradeFirm Fighting Parkinson's Hails Reviews, Upgrade
www.baystreet.ca - June 14 at 10:44 PM
Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT...Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT...
www.finanznachrichten.de - June 14 at 10:44 PM
NeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - StreetInsider.comNeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - StreetInsider.com
www.streetinsider.com - June 6 at 7:29 PM
NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - StreetInsider.comNeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - StreetInsider.com
www.streetinsider.com - June 6 at 12:25 AM
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ...NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ...
www.nasdaq.com - June 5 at 7:24 PM
NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 - GlobeNewswire (press release)NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 - GlobeNewswire (press release)
globenewswire.com - May 30 at 7:06 AM
NeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - StreetInsider.comNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - StreetInsider.com
www.streetinsider.com - May 24 at 6:53 PM
NeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS CongressNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress
www.streetinsider.com - May 24 at 10:29 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Neuroderm Ltd (NASDAQ NDRM) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.